Molecular targets in GI malignancies – A pathologist's perspective

Newer molecular diagnostics and improved understanding of cancer pathogenesis have identified multiple pathways that can be potentially targeted with the use of novel therapeutics in development. These developments have ushered cancer therapeutics in newer era of personalized medicine. Same is refle...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Satyajit Pawar, Atul Sharma
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Medknow Publications 2021
Materias:	gastrointestinal cancer molecular targets monoclonal antibodies targeted therapy tyrosine kinase inhibitors Pathology RB1-214 Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/171d9dfced4441d6a20268cc176da3e6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:171d9dfced4441d6a20268cc176da3e6
record_format	dspace
spelling	oai:doaj.org-article:171d9dfced4441d6a20268cc176da3e62021-12-02T17:28:22ZMolecular targets in GI malignancies – A pathologist's perspective0377-492910.4103/IJPM.IJPM_1239_20https://doaj.org/article/171d9dfced4441d6a20268cc176da3e62021-01-01T00:00:00Zhttp://www.ijpmonline.org/article.asp?issn=0377-4929;year=2021;volume=64;issue=5;spage=43;epage=51;aulast=Pawarhttps://doaj.org/toc/0377-4929Newer molecular diagnostics and improved understanding of cancer pathogenesis have identified multiple pathways that can be potentially targeted with the use of novel therapeutics in development. These developments have ushered cancer therapeutics in newer era of personalized medicine. Same is reflected on current management strategies for advanced gastrointestinal malignancies. Molecular profiling for BRAF and RAS is standard for colorectal cancer while Her2 and PDL1 status is needed for planning therapy of advanced gastroesophageal cancers. Tissue agnostic markers like MSI, TMB and NTRK are making headways in therapeutic armamentarium. While newer targeted therapies against FGFR, EGFR, PI3K-AKT, DDR pathways are showing promising results in initial studies. Here we review traditional as well as upcoming molecular markers in field of GI malignancies, methods of testing and evidence for rational use in clinical practice.Satyajit PawarAtul SharmaWolters Kluwer Medknow Publicationsarticlegastrointestinal cancermolecular targetsmonoclonal antibodiestargeted therapytyrosine kinase inhibitorsPathologyRB1-214MicrobiologyQR1-502ENIndian Journal of Pathology and Microbiology, Vol 64, Iss 5, Pp 43-51 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	gastrointestinal cancer molecular targets monoclonal antibodies targeted therapy tyrosine kinase inhibitors Pathology RB1-214 Microbiology QR1-502
spellingShingle	gastrointestinal cancer molecular targets monoclonal antibodies targeted therapy tyrosine kinase inhibitors Pathology RB1-214 Microbiology QR1-502 Satyajit Pawar Atul Sharma Molecular targets in GI malignancies – A pathologist's perspective
description	Newer molecular diagnostics and improved understanding of cancer pathogenesis have identified multiple pathways that can be potentially targeted with the use of novel therapeutics in development. These developments have ushered cancer therapeutics in newer era of personalized medicine. Same is reflected on current management strategies for advanced gastrointestinal malignancies. Molecular profiling for BRAF and RAS is standard for colorectal cancer while Her2 and PDL1 status is needed for planning therapy of advanced gastroesophageal cancers. Tissue agnostic markers like MSI, TMB and NTRK are making headways in therapeutic armamentarium. While newer targeted therapies against FGFR, EGFR, PI3K-AKT, DDR pathways are showing promising results in initial studies. Here we review traditional as well as upcoming molecular markers in field of GI malignancies, methods of testing and evidence for rational use in clinical practice.
format	article
author	Satyajit Pawar Atul Sharma
author_facet	Satyajit Pawar Atul Sharma
author_sort	Satyajit Pawar
title	Molecular targets in GI malignancies – A pathologist's perspective
title_short	Molecular targets in GI malignancies – A pathologist's perspective
title_full	Molecular targets in GI malignancies – A pathologist's perspective
title_fullStr	Molecular targets in GI malignancies – A pathologist's perspective
title_full_unstemmed	Molecular targets in GI malignancies – A pathologist's perspective
title_sort	molecular targets in gi malignancies – a pathologist's perspective
publisher	Wolters Kluwer Medknow Publications
publishDate	2021
url	https://doaj.org/article/171d9dfced4441d6a20268cc176da3e6
work_keys_str_mv	AT satyajitpawar moleculartargetsingimalignanciesapathologistsperspective AT atulsharma moleculartargetsingimalignanciesapathologistsperspective
_version_	1718380717723877376

Molecular targets in GI malignancies – A pathologist's perspective

Ejemplares similares